Susquehanna International Group
INO icon

Susquehanna International Group’s Inovio Pharmaceuticals INO Stock Holding History

Susquehanna International Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$468K Buy
268,700
+197,400
+277% +$325K ﹤0.01% 9844
2025
Q4 		$124K Sell
71,300
-106,100
-60% -$234K ﹤0.01% 11328
2025
Q3 		$415K Buy
177,400
+129,100
+267% +$247K ﹤0.01% 9392
2025
Q2 		$98.5K Buy
+48,300
New +$92.6K ﹤0.01% 11805
2025
Q1 		– Sell
-132,500
Closed -$242K – 12946
2024
Q4 		$242K Sell
132,500
-59,600
-31% -$264K ﹤0.01% 10283
2024
Q3 		$1.11M Sell
192,100
-60,800
-24% -$501K ﹤0.01% 6549
2024
Q2 		$2.04M Sell
252,900
-5,500
-2% -$57.9K ﹤0.01% 5059
2024
Q1 		$3.59M Buy
+258,400
New +$2.23M ﹤0.01% 4179
2023
Q3 		– Sell
-4,050
Closed -$21.9K – 12450
2023
Q2 		$21.9K Sell
4,050
-9,525
-70% -$76.8K ﹤0.01% 11617
2023
Q1 		$134K Sell
13,575
-5,833
-30% -$99.4K ﹤0.01% 11025
2022
Q4 		$363K Buy
19,408
+5,416
+39% +$123K ﹤0.01% 8639
2022
Q3 		$290K Sell
13,992
-12,366
-47% -$317K ﹤0.01% 9876
2022
Q2 		$547K Buy
26,358
+8,375
+47% +$236K ﹤0.01% 8047
2022
Q1 		$775K Sell
17,983
-8,125
-31% -$366K ﹤0.01% 7799
2021
Q4 		$1.56M Sell
26,108
-14,600
-36% -$1.17M ﹤0.01% 6115
2021
Q3 		$3.5M Sell
40,708
-20,117
-33% -$2.02M ﹤0.01% 4624
2021
Q2 		$6.77M Sell
60,825
-9,975
-14% -$958K ﹤0.01% 3491
2021
Q1 		$7.88M Sell
70,800
-64,333
-48% -$8.46M ﹤0.01% 3159
2020
Q4 		$14.4M Sell
135,133
-2,484
-2% -$331K ﹤0.01% 2082
2020
Q3 		$19.2M Sell
137,617
-49,108
-26% -$10.2M ﹤0.01% 1524
2020
Q2 		$60.4M Buy
186,725
+129,158
+224% +$20.7M 0.01% 726
2020
Q1 		$5.14M Buy
57,567
+51,542
+855% +$3.18M ﹤0.01% 2535
2019
Q4 		$239K Buy
6,025
+5,058
+523% +$152K ﹤0.01% 8441
2019
Q3 		$24K Sell
967
-241
-20% -$7.33K ﹤0.01% 9926
2019
Q2 		$43K Sell
1,208
-1,334
-52% -$53K ﹤0.01% 9874
2019
Q1 		$114K Sell
2,542
-3,250
-56% -$164K ﹤0.01% 8191
2018
Q4 		$278K Sell
5,792
-3,783
-40% -$230K ﹤0.01% 7137
2018
Q3 		$639K Buy
9,575
+5,358
+127% +$298K ﹤0.01% 6088
2018
Q2 		$198K Buy
4,217
+1,942
+85% +$107K ﹤0.01% 8618
2018
Q1 		$129K Buy
2,275
+692
+44% +$37.5K ﹤0.01% 8602
2017
Q4 		$78K Sell
1,583
-9,709
-86% -$602K ﹤0.01% 8778
2017
Q3 		$859K Sell
11,292
-6,266
-36% -$466K ﹤0.01% 5548
2017
Q2 		$1.65M Buy
17,558
+8,575
+95% +$733K ﹤0.01% 4268
2017
Q1 		$714K Buy
8,983
+4,825
+116% +$384K ﹤0.01% 5827
2016
Q4 		$346K Sell
4,158
-15,909
-79% -$1.44M ﹤0.01% 7705
2016
Q3 		$2.24M Buy
20,067
+7,800
+64% +$862K ﹤0.01% 3370
2016
Q2 		$1.36M Sell
12,267
-3,183
-21% -$387K ﹤0.01% 4239
2016
Q1 		$1.61M Buy
15,450
+6,575
+74% +$508K ﹤0.01% 4175
2015
Q4 		$716K Sell
8,875
-7,992
-47% -$636K ﹤0.01% 6096
2015
Q3 		$1.17M Buy
16,867
+6,692
+66% +$583K ﹤0.01% 5380
2015
Q2 		$996K Buy
10,175
+6,250
+159% +$668K ﹤0.01% 6224
2015
Q1 		$384K Sell
3,925
-767
-16% -$74.3K ﹤0.01% 7572
2014
Q4 		$517K Buy
4,692
+617
+15% +$75.4K ﹤0.01% 7143
2014
Q3 		$482K Sell
4,075
-19,383
-83% -$2.42M ﹤0.01% 7282
2014
Q2 		$3.04M Buy
+23,458
New +$2.77M ﹤0.01% 3899

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's INO Position: Q1 2026 in Review

Susquehanna International Group reduced its Inovio Pharmaceuticals (INO) stake by 77% in Q1 2026, selling an estimated $319K and leaving 56,862 shares worth $98.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12352.

Susquehanna International Group first reported a position in INO in Q2 2013 and has held it in 45 quarters since. The position peaked at $14.3M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Susquehanna International Group held 56,862 shares of Inovio Pharmaceuticals worth $98.9K as of Q1 2026.
  • Susquehanna International Group sold 194,088 Inovio Pharmaceuticals shares in Q1 2026, an estimated $319K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12352 holding.
  • Susquehanna International Group first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Inovio Pharmaceuticals position peaked at $14.3M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.